发明申请
US20130202592A1 Composition for the Anti-Cancer Metastasis Containing DLK1-Fc Fusion Protein as an Effective Ingredient
有权
含有DLK1-Fc融合蛋白作为有效成分的抗癌转移的组成
- 专利标题： Composition for the Anti-Cancer Metastasis Containing DLK1-Fc Fusion Protein as an Effective Ingredient
- 专利标题（中）： 含有DLK1-Fc融合蛋白作为有效成分的抗癌转移的组成
-
申请号： US13142818申请日： 2010-04-13
-
公开(公告)号： US20130202592A1公开(公告)日： 2013-08-08
- 发明人: Young Woo Park , Kiwon Jo , Donghee Lee , Jung Yu , Ji Hyun Park , Chan-Woong Park , Eun Jin Kim , Yun Jung Park
- 申请人： Young Woo Park , Kiwon Jo , Donghee Lee , Jung Yu , Ji Hyun Park , Chan-Woong Park , Eun Jin Kim , Yun Jung Park
- 申请人地址： KR Daejeon
- 专利权人： Korea Research Institute of Bioscience and Biotechnology
- 当前专利权人： Korea Research Institute of Bioscience and Biotechnology
- 当前专利权人地址： KR Daejeon
- 优先权： KR10-2010-0023180 20100316
- 国际申请： PCT/KR10/02277 WO 20100413
- 主分类号： C07K16/00
- IPC分类号： C07K16/00 ; C07K14/435
摘要：
A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.
公开/授权文献
信息查询
